Randomized	0	10	O
,	10	11	O
open	12	16	O
label	17	22	O
,	22	23	O
prospective	24	35	O
study	36	41	O
on	42	44	O
the	45	48	O
effect	49	55	O
of	56	58	O
zoledronic	59	69	B-Drug_or_compound
acid	70	74	I-Drug_or_compound
on	75	77	O
the	78	81	O
prevention	82	92	O
of	93	95	O
bone	96	100	B-Pathological_formation
metastases	101	111	I-Pathological_formation
in	112	114	O
patients	115	123	B-Organism
with	124	128	O
recurrent	129	138	O
solid	139	144	B-Pathological_formation
tumors	145	151	I-Pathological_formation
that	152	156	O
did	157	160	O
not	161	164	O
present	165	172	O
with	173	177	O
bone	178	182	B-Pathological_formation
metastases	183	193	I-Pathological_formation
at	194	196	O
baseline	197	205	O
.	205	206	O

OBJECTIVES	208	218	O
:	218	219	O
Bisphosphonates	220	235	B-Drug_or_compound
have	236	240	O
been	241	245	O
used	246	250	O
successfully	251	263	O
in	264	266	O
the	267	270	O
treatment	271	280	O
of	281	283	O
hypercalcemia	284	297	O
and	298	301	O
to	302	304	O
reduce	305	311	O
skeletal	312	320	B-Anatomical_system
-	320	321	O
related	321	328	O
complications	329	342	O
of	343	345	O
bone	346	350	B-Pathological_formation
metastases	351	361	I-Pathological_formation
.	361	362	O

Recent	363	369	O
in	370	372	O
vitro	373	378	O
and	379	382	O
in	383	385	O
vivo	386	390	O
evidence	391	399	O
suggest	400	407	O
that	408	412	O
they	413	417	O
may	418	421	O
also	422	426	O
have	427	431	O
direct	432	438	O
antitumor	439	448	O
effects	449	456	O
via	457	460	O
induction	461	470	O
of	471	473	O
apoptosis	474	483	O
,	483	484	O
inhibition	485	495	O
of	496	498	O
the	499	502	O
invasive	503	511	O
potential	512	521	O
of	522	524	O
tumor	525	530	B-Cell
cell	531	535	I-Cell
lines	536	541	I-Cell
in	542	544	O
vitro	545	550	O
,	550	551	O
inhibition	552	562	O
of	563	565	O
angiogenesis	566	578	O
,	578	579	O
and	580	583	O
reduction	584	593	O
in	594	596	O
tumor	597	602	B-Pathological_formation
growth	603	609	O
indirectly	610	620	O
via	621	624	O
effects	625	632	O
on	633	635	O
accessory	636	645	B-Cell
cells	646	651	I-Cell
.	651	652	O

This	653	657	O
is	658	660	O
a	661	662	O
randomized	663	673	O
,	673	674	O
open	675	679	O
label	680	685	O
,	685	686	O
prospective	687	698	O
study	699	704	O
that	705	709	O
examined	710	718	O
the	719	722	O
effect	723	729	O
of	730	732	O
preventive	733	743	O
zoledronic	744	754	B-Drug_or_compound
acid	755	759	I-Drug_or_compound
treatment	760	769	O
on	770	772	O
the	773	776	O
development	777	788	O
of	789	791	O
bone	792	796	B-Pathological_formation
metastases	797	807	I-Pathological_formation
in	808	810	O
patients	811	819	B-Organism
with	820	824	O
recurrent	825	834	O
solid	835	840	B-Pathological_formation
tumors	841	847	I-Pathological_formation
,	847	848	O
without	849	856	O
bone	857	861	B-Pathological_formation
metastases	862	872	I-Pathological_formation
at	873	875	O
the	876	879	O
time	880	884	O
of	885	887	O
randomization	888	901	O
.	901	902	O

METHODS	903	910	O
:	910	911	O
Forty	912	917	O
patients	918	926	B-Organism
with	927	931	O
recurrent	932	941	O
or	942	944	O
metastatic	945	955	O
advanced	956	964	O
cancer	965	971	O
,	971	972	O
without	973	980	O
bone	981	985	B-Pathological_formation
metastases	986	996	I-Pathological_formation
,	996	997	O
were	998	1002	O
randomized	1003	1013	O
into	1014	1018	O
the	1019	1022	O
trial	1023	1028	O
to	1029	1031	O
either	1032	1038	O
receive	1039	1046	O
zoledronic	1047	1057	B-Drug_or_compound
acid	1058	1062	I-Drug_or_compound
or	1063	1065	O
no	1066	1068	O
treatment	1069	1078	O
.	1078	1079	O

Patients	1080	1088	B-Organism
were	1089	1093	O
followed	1094	1102	O
up	1103	1105	O
until	1106	1111	O
bone	1112	1116	B-Pathological_formation
metastases	1117	1127	I-Pathological_formation
were	1128	1132	O
established	1133	1144	O
.	1144	1145	O

RESULTS	1146	1153	O
:	1153	1154	O
The	1155	1158	O
percentage	1159	1169	O
of	1170	1172	O
patients	1173	1181	B-Organism
being	1182	1187	O
bone	1188	1192	B-Pathological_formation
metastases	1193	1203	I-Pathological_formation
free	1204	1208	O
at	1209	1211	O
12	1212	1214	O
mo	1215	1217	O
was	1218	1221	O
60	1222	1224	O
%	1224	1225	O
in	1226	1228	O
the	1229	1232	O
zoledronic	1233	1243	B-Drug_or_compound
acid	1244	1248	I-Drug_or_compound
and	1249	1252	O
10	1253	1255	O
%	1255	1256	O
in	1257	1259	O
the	1260	1263	O
control	1264	1271	O
group	1272	1277	O
(	1278	1279	O
p	1279	1280	O
less	1281	1285	O
than	1286	1290	O
0	1291	1292	O
.	1292	1293	O
0005	1293	1297	O
)	1297	1298	O
,	1298	1299	O
while	1300	1305	O
the	1306	1309	O
percentages	1310	1321	O
at	1322	1324	O
18	1325	1327	O
mo	1328	1330	O
were	1331	1335	O
20	1336	1338	O
%	1338	1339	O
and	1340	1343	O
5	1344	1345	O
%	1345	1346	O
respectively	1347	1359	O
(	1360	1361	O
p	1361	1362	O
=	1362	1363	O
0	1363	1364	O
.	1364	1365	O
0002	1365	1369	O
)	1369	1370	O
.	1370	1371	O

CONCLUSIONS	1372	1383	O
:	1383	1384	O
The	1385	1388	O
results	1389	1396	O
have	1397	1401	O
shown	1402	1407	O
that	1408	1412	O
bisphosphonates	1413	1428	B-Drug_or_compound
as	1429	1431	O
adjuvant	1432	1440	O
treatment	1441	1450	O
might	1451	1456	O
be	1457	1459	O
useful	1460	1466	O
for	1467	1470	O
the	1471	1474	O
prevention	1475	1485	O
of	1486	1488	O
bone	1489	1493	B-Pathological_formation
metastases	1494	1504	I-Pathological_formation
;	1504	1505	O
however	1506	1513	O
,	1513	1514	O
there	1515	1520	O
is	1521	1523	O
need	1524	1528	O
for	1529	1532	O
blinded	1533	1540	O
randomized	1541	1551	O
data	1552	1556	O
before	1557	1563	O
such	1564	1568	O
an	1569	1571	O
approach	1572	1580	O
would	1581	1586	O
be	1587	1589	O
confirmed	1590	1599	O
.	1599	1600	O

In	1601	1603	O
the	1604	1607	O
meantime	1608	1616	O
preventive	1617	1627	O
use	1628	1631	O
of	1632	1634	O
bisphosphonates	1635	1650	B-Drug_or_compound
in	1651	1653	O
patients	1654	1662	B-Organism
without	1663	1670	O
any	1671	1674	O
bone	1675	1679	B-Pathological_formation
metastases	1680	1690	I-Pathological_formation
should	1691	1697	O
not	1698	1701	O
be	1702	1704	O
used	1705	1709	O
outside	1710	1717	O
the	1718	1721	O
scope	1722	1727	O
of	1728	1730	O
a	1731	1732	O
clinical	1733	1741	O
trial	1742	1747	O
.	1747	1748	O

